Stockscreener 앱 받기
222.76
4.01%
8.595
시간 외 거래:
220.22
-2.54
-1.14%
전일 마감가:
$214.16
열려 있는:
$216.43
하루 거래량:
10.74M
Relative Volume:
0.53
시가총액:
$88.93B
수익:
$2.23B
순이익/손실:
$-3.19B
주가수익비율:
-27.35
EPS:
-8.1462
순현금흐름:
$-1.60B
1주 성능:
+9.93%
1개월 성능:
+9.49%
6개월 성능:
+387.23%
1년 성능:
+801.86%
1일 변동 폭
$215.35
$225.00
1주일 범위
$179.53
$225.00
52주 변동 폭
$22.28
$254.48
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2026-09-30 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2026-09-03 | 다운그레이드 | Rothschild & Co Redburn | Neutral → Sell |
| 2026-08-28 | 업그레이드 | Argus | Hold → Buy |
| 2026-08-25 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2026-08-19 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-08-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Zacks Investment Research
Will Moderna Soar on Nov. 6? - The Motley Fool
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility - The Motley Fool
Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Breakfast News: A Conversation With Moderna’s CEO - The Motley Fool
American Tower (AMT) jumps 8% at the open, towering over a 385-stock board - 24/7 Wall St.
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? - The Motley Fool
Moderna Wins Top Employer Status - Baystreet.ca
Capital Group Global Growth (CGGO) Buys $121.1 Million More Moderna on Oct. 21 - Yahoo Finance
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports - The Motley Fool
Moderna Sheds $12 Billion in a Single Session After a 14% Drop - 24/7 Wall St.
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice - The Motley Fool
Moderna MRNA Breaks to a New 52-Week High at $242.08 - 24/7 Wall St.
Merck & (MRK) Stock Price, News & Analysis - 24/7 Wall St.
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027? - The Motley Fool
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Australia
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Nigeria
Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com UK
Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool
Moderna Executive Stephen Hoge Announces Intent to Sell 39,145 Shares Under Rule 144 - Kalkine Media
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's Why Moderna (MRNA) Fell More Than Broader Market - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Lori Trahan Stock Trades and Disclosures - TechGraph
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell? - The Motley Fool
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Moderna surges 12.6% after hours, adding roughly $11 billion in value - 24/7 Wall St.
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock? - Zacks Investment Research
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now? - Zacks Investment Research
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com India
Frank Baker joins IBM's board, bringing a private equity edge to a $213.5 billion tech giant - 24/7 Wall St.
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com Canada
Form 4 Moderna Inc For: 7 October By Investing.com - Investing.com UK
Moderna (MRNA) CFO has 704 shares withheld for taxes after converting a stock grant. - Stock Titan
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety - Benzinga
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Oct 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,675,710 |
| Hoge Stephen | Officer |
Oct 15 '26 |
Proposed Sale |
220.72 |
39,145 |
8,640,033 |
0 |
| Hoge Stephen | President |
Oct 15 '26 |
Sale |
220.72 |
39,145 |
8,640,084 |
1,636,565 |
| Hoge Stephen | Officer |
Oct 14 '26 |
Proposed Sale |
213.48 |
39,224 |
8,373,519 |
0 |
| Hoge Stephen | President |
Oct 14 '26 |
Sale |
213.48 |
39,224 |
8,373,453 |
1,599,258 |
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | Officer |
Sep 15 '26 |
Proposed Sale |
146.07 |
40,281 |
5,883,709 |
0 |
| Hoge Stephen | President |
Sep 14 '26 |
Option Exercise |
12.21 |
76,453 |
933,491 |
1,566,152 |
| Hoge Stephen | Officer |
Sep 14 '26 |
Proposed Sale |
144.13 |
40,294 |
5,807,746 |
0 |
0.68%
0.48%
자본화:
|
볼륨(24시간):